Laurell M, Stenflo J, Carlson T H
Department of Clinical Chemistry, Malmö General Hospital, Sweden.
Blood. 1990 Dec 1;76(11):2290-5.
The rates of clearance and catabolism of human protein C inhibitor (PCI) and human alpha 1-antitrypsin (alpha 1-AT) and their complexes with human activated protein C (APC) were studied in the rabbit. The radioiodinated-free inhibitors had biologic half-lives of 23.4 and 62.1 hours, respectively, while the corresponding *I-labeled activated-protein C complexes were cleared with half-lives of 19.6 +/- 3.1 and 72.2 +/- 6.1 minutes. Complex clearances were linked to their catabolism as shown by a correlation between clearance and the appearance of free radioiodine in the plasma. Thus, the difference in the rates of catabolism would result in a fivefold greater amount of alpha 1-AT-APC complex than PCI-APC complex 1 hour after the formation of equal amounts of these in vivo. These results lead to the conclusion that the relative contribution of PCI and alpha 1-AT to the physiologic inhibition of APC cannot be determined only from the rates of the formation of these complexes in vitro, or from measurement of their levels in plasma. The APC-PCI complex is unstable as compared with the APC-alpha 1-AT complex, compounding the problem of estimating rates of complex formation from their levels in plasma.
在兔体内研究了人蛋白C抑制剂(PCI)、人α1 -抗胰蛋白酶(α1 - AT)及其与人活化蛋白C(APC)形成的复合物的清除率和分解代谢率。无放射性碘标记的抑制剂的生物学半衰期分别为23.4小时和62.1小时,而相应的碘标记的活化蛋白C复合物的清除半衰期分别为19.6±3.1分钟和72.2±6.1分钟。复合物的清除与其分解代谢相关,血浆中清除率与游离放射性碘的出现之间存在相关性。因此,在体内形成等量的这些复合物1小时后,α1 - AT - APC复合物的分解代谢率差异将导致其含量比PCI - APC复合物高五倍。这些结果得出结论,不能仅根据体外这些复合物的形成速率或血浆中它们的水平测量来确定PCI和α1 - AT对APC生理抑制的相对贡献。与APC - α1 - AT复合物相比,APC - PCI复合物不稳定,这使得从血浆中它们的水平估计复合物形成速率的问题更加复杂。